Skip to content
Clinical Trials – home
NorwayBack to Norway

Clinical trials in Gjettum – page 38

616 clinical trials in Gjettum, Norway across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

NorwayOur site in NorwayKliniske-Studier.no(opens in a new tab)
Gjettum at a glance
616
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

616 trials in Gjettum

Open in trial search

Study on the Effects of Losartan Potassium on Brain Tumors in Patients with Glioblastoma or Brain Metastases from Non-Small-Cell Lung Cancer

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Losartan Potassium
  • Sponsor:Oslo University Hospital HF

Oesophageal carcinoma

Not recruiting

Study on the Safety of Radiation and Nivolumab for Patients with Esophageal Cancer

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:Oslo University Hospital HF

Myasthenia gravis

Not recruiting

Study on Efgartigimod IV for Adults with Seronegative Generalized Myasthenia Gravis

Registered drug
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Efgartigimod Alfa
  • Sponsor:Argenx

Study on the Safety and Effects of RLYB212 in Pregnant Women at Risk for Fetal and Neonatal Alloimmune Thrombocytopenia

InvestigationalNo placebo
Countries:NorwayNorway
  • Participants:18–64 years
  • Substances:RB 212
  • Sponsor:Rallybio Ipa LLC

Ovarian cancer

Not recruiting

Study on the Safety and Tolerability of KAND567 and Carboplatin for Women with Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Kancera AB

Study on the Effect of Extending Imatinib Treatment from Three to Five Years for Patients with High-Risk Gastrointestinal Stromal Tumor (GIST)

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Imatinib
  • Sponsor:Region Skane

Plasma cell myeloma

Not recruiting

Study on KRd Consolidation for Multiple Myeloma Patients with Positive PET-CT: Carfilzomib, Lenalidomide, and Dexamethasone Treatment

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Carfilzomib
  • Sponsor:Oslo University Hospital HF

Malignant glioma

Not recruiting

Study of tovorafenib versus standard chemotherapy as first treatment for children with low-grade glioma with RAF gene changes

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:0–17 years · 18–64 years
  • Substances:Carboplatin
  • Sponsor:Day One Biopharmaceuticals Inc.

Study comparing tenecteplase and acetylsalicylic acid in patients with central retinal artery occlusion within 4.

Registered drug
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Acetylsalicylic Acid
  • Sponsor:Oslo University Hospital HF

Plasma cell myeloma

Not recruiting

Study of Selinexor, Bortezomib, and Lenalidomide with Dexamethasone for Newly Diagnosed Multiple Myeloma Patients Not Eligible for Transplant

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Odense University Hospital

Hidradenitis

Not recruiting

Study of lutikizumab compared to placebo in adults and adolescents (age 12 and older) with moderate to severe Hidradenitis Suppurativa

Investigational
Countries:NorwayNorway
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Lutikizumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Acute myeloid leukaemia+1

Not recruiting

Study of Ivosidenib or Enasidenib with Chemotherapy for Patients with Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome with IDH1 or IDH2 Mutation

Investigational
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Enasidenib Mesilate
  • Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Other cities in Norway

The busiest research cities in the country

All 53 cities in Norway

Clinical research in Gjettum

What the registry says about research in the country

01 Gastroenterology Research

Innovative trials focusing on inflammatory bowel diseases, including studies of combination therapies for both Crohn's Disease and Ulcerative Colitis. Research aims to evaluate new treatment approaches using targeted biological agents.

  • Crohn's Disease Management
  • Ulcerative Colitis Treatment
  • Combination Therapy Assessment

These studies explore dual-therapy approaches to improve clinical outcomes for patients with moderate to severe disease activity.

02 Cardiovascular Studies

Research focusing on prevention and treatment of stroke and cardiac conditions, including innovative approaches for managing atrial fibrillation and evaluating new anticoagulation therapies.

  • Stroke Prevention
  • Atrial Fibrillation Management
  • Thrombolysis Research

Trials aim to improve outcomes in acute ischemic stroke and prevent cardiac complications.

03 Musculoskeletal Medicine

Comprehensive research into orthopedic conditions, including studies on osteoarthritis, carpal tunnel syndrome, and hip fracture treatments.

  • Joint Disease Management
  • Surgical vs. Conservative Treatment
  • Post-fracture Care

Investigations compare different treatment approaches and timing of interventions for optimal patient outcomes.

04 Infectious Disease Research

Studies addressing various infectious conditions including COVID-19 and mpox, evaluating novel therapeutic approaches and treatment strategies.

  • COVID-19 Treatment Trials
  • Mpox Management
  • Antiviral Therapy Assessment

Research focuses on understanding disease progression and testing new therapeutic interventions.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.